12:50 pm
Investors Club

Lifesomix

Pitch
Biotech & Therapeutics

Peptide-based therapeutic targeting NAFLD/NASH by modulating the SOCS1–JAK/STAT pathway to reverse steatosis, inflammation, and fibrosis, with strong in vivo and in vitro proof of concept.

Related activities

Pitch
AURAX Technologies
10:50 am
Investors Club
View more
Pitch
TraffikGene
1:10 pm
Investors Club
View more
Pitch
ECOCITOR
2:10 pm
Investors Club
View more
Back to agenda